Analysts Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) PT at $8.60

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six research firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $8.60.

A number of equities research analysts recently commented on the company. StockNews.com upgraded Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Craig Hallum cut their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, January 22nd. Finally, JMP Securities lowered their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a report on Thursday, January 30th.

Insiders Place Their Bets

In other news, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This represents a 6.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the sale, the chief executive officer now owns 1,160,634 shares of the company's stock, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 192,381 shares of company stock worth $338,591 over the last 90 days. Company insiders own 12.90% of the company's stock.

Remove Ads

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV grew its position in Ironwood Pharmaceuticals by 59.3% during the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 3,198 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Ironwood Pharmaceuticals by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock worth $150,000 after purchasing an additional 3,209 shares during the period. Quantinno Capital Management LP grew its position in Ironwood Pharmaceuticals by 40.0% during the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company's stock worth $79,000 after purchasing an additional 5,482 shares during the period. Swiss National Bank grew its position in Ironwood Pharmaceuticals by 2.2% during the 4th quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company's stock worth $1,252,000 after purchasing an additional 6,000 shares during the period. Finally, Teacher Retirement System of Texas grew its position in Ironwood Pharmaceuticals by 19.6% during the 4th quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company's stock worth $190,000 after purchasing an additional 7,020 shares during the period.

Ironwood Pharmaceuticals Stock Performance

Shares of Ironwood Pharmaceuticals stock traded up $0.04 during trading hours on Monday, hitting $1.49. The company's stock had a trading volume of 83,276 shares, compared to its average volume of 2,313,198. The business has a 50 day moving average price of $2.44 and a two-hundred day moving average price of $3.55. Ironwood Pharmaceuticals has a 12-month low of $1.34 and a 12-month high of $9.23. The company has a market cap of $237.64 million, a PE ratio of -49.50 and a beta of 0.37.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.08). The business had revenue of $90.55 million during the quarter, compared to analysts' expectations of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. As a group, research analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.